Watch Ticker

Satsuma Pharmaceuticals, Inc. Common Stock

Go to Satsuma Pharmaceuticals, Inc. Common Stock Website

$1.10

(%)

Live

Previous Close

$1.1

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

Day Vol.

Previous Day Vol.

Currency

Primary Exchange

Nasdaq

...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Satsuma Pharmaceuticals - Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine

SOUTH SAN FRANCISCO, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company today announced that its 505(b)(2) new drug application (NDA) for STS101, a novel and investigational therapeutic product candidate for the acute treatment of migraine, has been accepted for review by the FDA.

Related tickers: STSA.

Read Full Article

Satsuma Pharmaceuticals - Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting

SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a development-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that three abstracts highlighting STS101 were accepted at the American Academy of Neurology’s (AAN) 75th Annual Meeting. The 2023 meeting will be held in a hybrid virtual and in-person format in Boston, Massachusetts from Saturday, April 22 to Thursday, April 27, 2023. Full abstracts are now available on the AAN website.

Related tickers: STSA.

Read Full Article

Trending Tickers

Please sign in to view